» Articles » PMID: 28792506

Can Magnetic Resonance Spectroscopy Differentiate Malignant and Benign Causes of Lymphadenopathy? An In-vitro Approach

Overview
Journal PLoS One
Date 2017 Aug 10
PMID 28792506
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphadenopathy continues to be a common problem to radiologists and treating physicians because of the difficulty in confidently categorizing a node as being benign or malignant using standard diagnostic techniques. The goal of our research was to assess whether magnetic resonance (MR) spectroscopy contains the necessary information to allow differentiation of benign from malignant lymph nodes in an in-vitro approach using a modern pattern recognition method. Tissue samples from a tissue bank were analyzed on a nuclear magnetic resonance (NMR) spectrometer. A total of 69 samples were studied. The samples included a wide variety of malignant and benign etiologies. Using 45 samples, we initially created a model which was able to predict if a certain spectrum originates from benign or malignant lymph nodes using a pattern-recognition technique which takes into account the entire magnetic spectrum rather than single peaks alone. The remaining 24 samples were blindly loaded in the model to assess its performance. We obtained an excellent accuracy in differentiating benign and malignant lymphadenopathy using the model. It correctly differentiated as malignant or benign, in a blinded fashion, all of the malignant samples (13 of 13) and 10 out of the 11 benign samples. We thus showed that magnetic spectroscopy is able to differentiate benign from malignant causes of lymphadenopathy. Additional experiments were performed to verify that the differentiating abilities of our model were not due to differential tissue decay in between benign and malignant tissues. If future experiments demonstrate that a similar approach could be executed with standard MR imaging, this technique could be useful as a problem-solving tool when assessing lymphadenopathy in general. Alternatively, our in-vitro technique could also be useful to pathologists faced with indeterminate pathologies of the lymph nodes after validating our results with a larger sample size.

Citing Articles

Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Rindi G, Wiedenmann B Nat Rev Endocrinol. 2020; 16(10):590-607.

PMID: 32839579 DOI: 10.1038/s41574-020-0391-3.


Computed tomography texture features can discriminate benign from malignant lymphadenopathy in pediatric patients: a preliminary study.

Cahalane A, Kilcoyne A, Tabari A, McDermott S, Gee M Pediatr Radiol. 2019; 49(6):737-745.

PMID: 30741316 DOI: 10.1007/s00247-019-04350-3.

References
1.
Yamazaki Y, Saitoh M, Notani K, Tei K, Totsuka Y, Takinami S . Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med. 2008; 22(3):177-84. DOI: 10.1007/s12149-007-0097-9. View

2.
King A, Yeung D, Ahuja A, Yuen E, Ho S, Tse G . Human cervical lymphadenopathy: evaluation with in vivo 1H-MRS at 1.5 T. Clin Radiol. 2005; 60(5):592-8. DOI: 10.1016/j.crad.2004.11.012. View

3.
Kumar A, Dutta R, Kannan U, Kumar R, Khilnani G, Gupta S . Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med. 2011; 6(1):11-6. PMC: 3023864. DOI: 10.4103/1817-1737.74270. View

4.
Dieterle F, Ross A, Schlotterbeck G, Senn H . Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006; 78(13):4281-90. DOI: 10.1021/ac051632c. View

5.
Tugnoli V, Schenetti L, Mucci A, Parenti F, Cagnoli R, Righi V . Ex vivo HR-MAS MRS of human meningiomas: a comparison with in vivo 1H MR spectra. Int J Mol Med. 2006; 18(5):859-69. View